Search

Aim To determine the effects of metformin or liraglutide on oxidative stress level and antioxidative enzymes gene ex - pression and activity in the blood and vessels of pre-diabet - ic obese elderly Sprague-Dawley (SD) rats of both sexes. Methods Male and female SD rats were assigned to the following groups: a) control group (fed with standard ro - dent chow); b) high-fat and high-carbohydrate diet (HSHFD) group fed with HSHFD from 20-65 weeks of age; c) HSHFD+metformin treatment (50 mg/kg/d s.c.); and d) HSHFD+liraglutide treatment (0.3 mg/kg/d s.c). Oxidative stress parameters (ferric reducing ability of plasma and thiobarbituric acid reactive substances) and superoxide dis - mutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity and gene expression were determined from serum, aortas, and surface brain blood vessels (BBV). Results HSHFD increased body weight in both sexes com - pared with the control group, while liraglutide prevented this increase. Blood glucose level did not change. The lira - glutide group had a significantly increased antioxidative ca - pacity compared with the HSHFD group in both sexes. The changes in antioxidative enzymes’ activities in plasma were more pronounced in male groups. The changes in gene ex - pression of antioxidative enzymes were more prominent in microvessels and may be attributed to weight gain preven - tion. Conclusions Obesity and antidiabetic drugs caused sexrelated differences in the level of antioxidative parameters. Liraglutide exhibited stronger antioxidative effects than metformin. These results indicate that weight gain due to HSHFD is crucial for developing oxidative stress and for in - hibiting antioxidative protective mechanisms

Aim To determine the effects of metformin or liraglutide on oxidative stress level and antioxidative enzymes gene ex - pression and activity in the blood and vessels of pre-diabet - ic obese elderly Sprague-Dawley (SD) rats of both sexes. Methods Male and female SD rats were assigned to the following groups: a) control group (fed with standard ro - dent chow); b) high-fat and high-carbohydrate diet (HSHFD) group fed with HSHFD from 20-65 weeks of age; c) HSHFD+metformin treatment (50 mg/kg/d s.c.); and d) HSHFD+liraglutide treatment (0.3 mg/kg/d s.c). Oxidative stress parameters (ferric reducing ability of plasma and thiobarbituric acid reactive substances) and superoxide dis - mutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity and gene expression were determined from serum, aortas, and surface brain blood vessels (BBV). Results HSHFD increased body weight in both sexes com - pared with the control group, while liraglutide prevented this increase. Blood glucose level did not change. The lira - glutide group had a significantly increased antioxidative ca - pacity compared with the HSHFD group in both sexes. The changes in antioxidative enzymes’ activities in plasma were more pronounced in male groups. The changes in gene ex - pression of antioxidative enzymes were more prominent in microvessels and may be attributed to weight gain preven - tion. Conclusions Obesity and antidiabetic drugs caused sexrelated differences in the level of antioxidative parameters. Liraglutide exhibited stronger antioxidative effects than metformin. These results indicate that weight gain due to HSHFD is crucial for developing oxidative stress and for in - hibiting antioxidative protective mechanisms

Csaba Bartos,1 Rita Ambrus,1 Gábor Katona,1 Tamás Sovány,1 Róbert Gáspár,2 Árpád Márki,3 Eszter Ducza,4 Anita Ivanov,4 Ferenc Tömösi,5 Tamás Janáky,5 Piroska Szabó-Révész1 1Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary; 2Faculty of Medicine, Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary; 3Faculty of Medicine, Department of Medical Physics and Informatics, University of Szeged, Szeged, Hungary; 4Faculty of Pharmacy, Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary; 5Interdisciplinary Excellence Centre, Department of Medical Chemistry, University of Szeged, Szeged, HungaryCorrespondence: Piroska Szabó-RévészFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös u 6, Szeged H-6720, HungaryTel +36 62 545 5722Fax +36 62 545 571Email revesz@pharm.u-szeged.huPurpose: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a further stabilizing agent because the final aim was to produce surfactant-free solid phase products as well.Methods: The solidified samples produced by fluidization and lyophilization (fluidMel, lyoMel) were examined for particle size, crystallinity, and in vitro release of Mel compared to similar parameters of nanoMel. The products were subjected to an animal experiment using per oral administration to verify their bioavailability.Results: Mel containing (1%) nanoMel sample was produced by wet milling p